Advanced Filters
noise

Tinnitus Clinical Trials

A listing of Tinnitus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 99 clinical trials

Mesenchymal Stromal Cells as Treatment for Digital Ulcers in Systemic Sclerosis

The MANUS Trial aims to examine the safety, feasibility and potential efficacy of intramuscularly injected allogeneic mesenchymal stromal cells as treatment for digital ulcers of systemic sclerosis.

18 - 100 years of age Both Phase 1/2
S Study Coordinator

Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases

A subset of autoimmune diseases (ADs) in children and young adults are life-threatening and unresponsive to conventional treatments. In these patients, the delivery of high dose immunosuppressive therapy followed by autologous stem cell transplant (ASCT) offers a treatment strategy capable of purging the pathogenic, autoreactive immune system and an opportunity …

8 - 25 years of age Both Phase 2
A Alain MEYER, MD

Search for Diagnostic and Prognostic Biomarkers in Systemic Sclerosis and Inflammatory Myopathies

Systemic sclerosis and inflammatory myopathies, which sometimes combine (scleromyositis), have shared pathophysiological elements. In both diseases, many cell subtypes are involved in damage to organs such as T lymphocytes, B lymphocytes, and unconventional (non-B, non-T) lymphocytes called innate lymphoid cell (ILC). The increasing complexity of our understanding of the immune …

18 - 100 years of age Both Phase N/A
H Huimin Meng, Doctor

Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases

Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID). Secondary purpose: To evaluate the pharmacokinetic (PK) profile of UTAA09 injection in patients with R/R AID. To evaluate the pharmacodynamic (PD) characteristics of UTAA09 injection in patients with R/R AID. To evaluate …

18 - 100 years of age Both Phase N/A
V Valérie PORQUET-BORDES, MD

Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study

Ectopic soft tissue calcifications or ossifications can complicate the course of numerous diseases; most of them are rare or very rare. Even if the clinical, radiological and pathological presentation of ectopic calcifications and ossifications are different, the same hypotheses are discussed considering their hypothetical pathophysiology. Indeed, high calcium phosphate product, …

6 - 100 years of age Both Phase 2
M Marie Hudson, MD MPH

Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis

The purpose of this study is to test the safety and efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UCMSC) for the treatment of Systemic Sclerosis (SSc).

18 - 100 years of age Both Phase 1/2

CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease

The investigational product is designed to effectively combat B cells in patients with autoimmune diseases. Autologous T cells enriched with CD4/CD8 are genetically engineered using a lentiviral vector to express chimeric antigen receptors (CARs) that target the CD19 antigen on the cell surface of B cells and their precursors. During …

18 - 100 years of age Both Phase 1/2
Q Qiong Fu, MD, PhD

Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

To evaluate the safety and efficacy of CD19-CAR-DNT cells in subjects with relapsed/refractory autoimmune diseases

18 - 65 years of age Both Phase 1
H Huji Xu, Doctor

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.

18 - 65 years of age Both Phase N/A
H Huji Xu, Doctor

Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease

This is an investigator-initiated trial to evaluate the safety and efficacy of anti-CD19-CD3E-CAR-T cells in the relapse or refractory autoimmune diseases.

18 - 65 years of age Both Phase N/A

Rewrite in simple language using AI